Astellas And Pfizer's XTANDI Shows Long-Term Survival Benefits In Metastatic Prostate Cancer
23/5 05:28
(RTTNews) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of overall survival benefits and a 30% reduction in the risk of death in men with metas...